Kunikowska Jolanta, Pełka Kacper, Tayara Omar, Królicki Leszek
Nuclear Medicine Department, Medical University of Warsaw, 02-091 Warsaw, Poland.
Department of Methodology, Laboratory of Center for Preclinical Research, Medical University of Warsaw, 02-091 Warsaw, Poland.
J Clin Med. 2022 Jun 9;11(12):3311. doi: 10.3390/jcm11123311.
The presence of prostate-specific membrane antigen (PSMA) on prostate cancer cells and its metastases allows its use in diagnostics using PET/CT. The aim of this study was to evaluate the usefulness of delayed phase images in the Ga-68-PSMA-11 PET/CT. Methods: 108 patients with prostate cancer (median age: 68.5 years, range: 49−83) were referred for Ga-68-PSMA-11 PET/CT due to biochemical relapse (PSA (prostate-specific antigen) (3.2 ± 5.4 ng/mL). Examinations were performed at 60 min, with an additional delayed phase of the pelvis region at 120−180 min. Results: The Ga-68-PSMA-11 PET/CT showed lesions in 86/108 (80%) patients; detection rate depending on the PSA level: 0.2 < PSA < 0.5 ng/mL vs. 0.5 ≤ PSA < 1.0 ng/mL vs. 1.0 ≤ PSA < 2.0 ng/mL vs. PSA ≥ 2.0 ng/mL was 56% (standard vs. delay: 56 vs. 56%) vs. 60% (52 vs. 60%) vs. 87% (83 vs. 87%) vs. 82% (77 vs. 82%) of patients, respectively. The delayed phase had an impact on the treatment in 14/86 patients (16%) (p < 0.05): 7 pts increased uptake was seen only after 60 min, which was interpreted as physiological or inflammatory accumulation; the delayed image showed increased accumulation in 7 patients only: 4 in regional lymph nodes, 1 in local recurrence, and 2 patients with local recurrence showed additional foci. Conclusions: Delayed phase of Ga-68-PSMA-11 PET/CT has an impact on treatment management in 16% of patients.
前列腺癌细胞及其转移灶上存在前列腺特异性膜抗原（PSMA），这使得其可用于PET/CT诊断。本研究的目的是评估镓-68-PSMA-11 PET/CT延迟期图像的效用。方法：108例前列腺癌患者（中位年龄：68.5岁，范围：49 - 83岁）因生化复发（前列腺特异性抗原（PSA）为3.2±5.4 ng/mL）接受镓-68-PSMA-11 PET/CT检查。检查在60分钟时进行，骨盆区域在120 - 180分钟时进行额外的延迟期扫描。结果：镓-68-PSMA-11 PET/CT在86/108（80%）例患者中发现病变；根据PSA水平的检出率：0.2 < PSA < 0.5 ng/mL vs. 0.5≤PSA < 1.0 ng/mL vs. 1.0≤PSA < 2.0 ng/mL vs. PSA≥2.0 ng/mL的患者分别为56%（标准期vs.延迟期：56% vs. 56%）vs. 60%（52% vs. 60%）vs. 87%（83% vs. 87%）vs. 82%（77% vs. 82%）。延迟期对14/86例患者（16%）的治疗有影响（p < 0.05）：7例患者仅在60分钟后摄取增加，这被解释为生理性或炎性聚集；延迟期图像仅在7例患者中显示摄取增加：4例在区域淋巴结，1例在局部复发，2例局部复发患者显示额外病灶。结论：镓-68-PSMA-11 PET/CT延迟期对16%的患者治疗管理有影响。
